Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
OBJECTIVES: After completing this activity, the participant should be able to: Describe DPP-4 inhibitors' mechanism of action in lowering blood glucose concentrations in patients with type 2 diabetes
Aronnes clinical trial for orforglipron, the rate of adverse events (meaning health issues that happened during the trial, including things likely not related to the drug itself) appeared to be slightly lower than whats seen with injectables
Your doctor will determine the frequency of the injection
These changes create NDP--MSH (Nle4, D-Phe7--MSH), which is approximately 100-1000 times more potent than native -MSH at the MC1R receptor and is resistant to enzymatic degradation
doi: 10.1016/s2213-8587(19)30249-9 31 ZhaoXWangMWenZLuZCuiLFuCet al
Likewise, understanding payer dynamics and patient affordability, and building strategies that remove access obstacles for target customers (e.g., co-pay and cash pay assistance programs that enable affordability to more patients) are important to support the realization of the full potential of this market, especially considering the economic demographics of diabetes and obesity patients
